Key Takeaway: The article discusses the neuroprotective effects of the Sigma-2 modulator CT2074 in a mouse model of ocular hypertension. Conducted by Donkor et al., the study highlights the potential of CT2074 as a therapeutic option for neuroprotection in ocular conditions. The findings are published in Experimental Eye Research, indicating a significant advancement in this area of research.
Price reaction · baseline $0.5421 (2024-10-28 close) · hit pre-market · 4 other CGTX headline(s) in the window, move may be shared
day 0 close
+5.1%
day 1
-2%
day 3 · peak
-13.1%
Market Sentiment Analysis
POSITIVE FACTORS
CT2074 shows potential as a neuroprotective agent.
The study provides promising results in a mouse model.
Research contributes to understanding ocular hypertension treatments.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Neuroprotective effect of Sigma-2 modulator CT2074 in a mouse model of ocular hypertension
Donkor N, Kiehlbauch CC, Pappenhagen N, et al.
Neuroprotective effect of Sigma-2 modulator CT2074 in a mouse model of ocular hypertension
Experimental Eye Research
Frequently Asked Questions
What is CT2074?
CT2074 is a Sigma-2 modulator studied for its neuroprotective effects.
What condition was CT2074 tested for?
CT2074 was tested in a mouse model of ocular hypertension.
Who conducted the study on CT2074?
The study was conducted by Donkor and colleagues.
Where was the study published?
The findings were published in Experimental Eye Research.